PTC Therapeutics | PTCT - Assets


PTC Therapeutics reported $2.9B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Cytokinetics USD 1.44B 210.92M Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Esperion Therapeutics USD 364.02M 16.93M Sep/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
Karyopharm Therapeutics USD 96.23M 8.65M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
TG Therapeutics USD 1.03B 322.41M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 868.81M 10.61M Sep/2025